Albany Molecular Research Stock Price, News & Analysis (NASDAQ:AMRI)

$21.74 0.00 (0.00 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$21.74
Today's Range$21.73 - $21.76
52-Week Range$13.01 - $22.17
Volume531,200 shs
Average Volume872,120 shs
Market Capitalization$937.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17

About Albany Molecular Research (NASDAQ:AMRI)

Albany Molecular Research logoAlbany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:AMRI
  • CUSIP: N/A
  • Web: www.amriglobal.com
Debt:
  • Debt-to-Equity Ratio: 0.62%
  • Current Ratio: 0.68%
  • Quick Ratio: 0.37%
Profitability:
  • Trailing EPS: ($1.43)
  • Net Margins: -5.93%
  • Return on Equity: -13.39%
  • Return on Assets: -3.42%
Misc:
  • Employees: 3,085
  • Outstanding Shares: 43,120,000
 

Frequently Asked Questions for Albany Molecular Research (NASDAQ:AMRI)

What is Albany Molecular Research's stock symbol?

Albany Molecular Research trades on the NASDAQ under the ticker symbol "AMRI."

How were Albany Molecular Research's earnings last quarter?

Albany Molecular Research, Inc. (NASDAQ:AMRI) posted its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.21 by $0.14. The biotechnology company earned $102.80 million during the quarter, compared to analyst estimates of $107.20 million. Albany Molecular Research had a negative return on equity of 13.39% and a negative net margin of 5.93%. View Albany Molecular Research's Earnings History.

Where is Albany Molecular Research's stock going? Where will Albany Molecular Research's stock price be in 2017?

4 brokerages have issued 12-month target prices for Albany Molecular Research's stock. Their predictions range from $18.00 to $18.00. On average, they expect Albany Molecular Research's share price to reach $18.00 in the next year. View Analyst Ratings for Albany Molecular Research.

Who are some of Albany Molecular Research's key competitors?

Who are Albany Molecular Research's key executives?

Albany Molecular Research's management team includes the folowing people:

  • William S. Marth, President, Chief Executive Officer, Director
  • Felicia Ladin, Chief Financial Officer, Senior Vice President, Treasurer
  • Lori M. Henderson Esq., Senior Vice President, General Counsel, Secretary
  • Christopher M Conway, Senior Vice President - Discovery and Development and Global Commercial Sales
  • , Bio & Compensation - 
  • Milton Boyer, Senior Vice President - Drug Product Manufacturing
  • , Bio & Compensation - 
  • Steven R. Hagen Ph.D., Senior Vice President - Manufacturing and Pharmaceuticals
  • George Svokos, Chief Commercial Officer and Senior Vice President, API
  • Jimmy Wang Ph.D., Chief Information Officer
  • , Bio & Compensation - 
  • Thomas E. D' Ambra Ph.D., Non-Executive Chairman of the Board
  • David H. Deming, Director

How do I buy Albany Molecular Research stock?

Shares of Albany Molecular Research can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Albany Molecular Research's stock price today?

One share of Albany Molecular Research stock can currently be purchased for approximately $21.74.

How big of a company is Albany Molecular Research?

Albany Molecular Research has a market capitalization of $937.41 million. Albany Molecular Research employs 3,085 workers across the globe.

How can I contact Albany Molecular Research?

Albany Molecular Research's mailing address is 21 Corporate Cir, PO Box 15098, ALBANY, NY 12203-5154, United States. The biotechnology company can be reached via phone at +1-518-4640279.


MarketBeat Community Rating for Albany Molecular Research (NASDAQ AMRI)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  209
MarketBeat's community ratings are surveys of what our community members think about Albany Molecular Research and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Albany Molecular Research (NASDAQ:AMRI)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 4 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $18.00 (17.20% downside)

Consensus Price Target History for Albany Molecular Research (NASDAQ:AMRI)

Price Target History for Albany Molecular Research (NASDAQ:AMRI)

Analysts' Ratings History for Albany Molecular Research (NASDAQ:AMRI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/12/2017First AnalysisDowngradeOverweight -> Equal WeightLowView Rating Details
6/8/2017J P Morgan Chase & CoDowngradeOverweight -> NeutralLowView Rating Details
6/6/2017William BlairDowngradeOutperform -> Market PerformLowView Rating Details
5/11/2017Morgan StanleyDowngradeOverweight -> Equal Weight$18.00HighView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Albany Molecular Research (NASDAQ:AMRI)

Earnings by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Earnings History by Quarter for Albany Molecular Research (NASDAQ AMRI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$0.12$0.13$161.43 million$163.80 millionViewListenView Earnings Details
2/21/2017Q416$0.48$0.34$221.30 million$191.30 millionViewListenView Earnings Details
11/8/2016Q316$0.13$0.17$160.75 million$151.70 millionViewListenView Earnings Details
5/10/2016Q1$0.21$0.07$107.20 million$102.80 millionViewListenView Earnings Details
2/17/2016Q415$0.36$0.40$133.40 million$126.40 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.11$95.15 million$101.40 millionViewListenView Earnings Details
8/4/2015Q215$0.18$0.19$85.00 million$85.20 millionViewListenView Earnings Details
5/5/2015Q115$0.15$0.20$81.50 million$75.10 millionViewN/AView Earnings Details
2/12/2015Q414$0.33$0.28$91.90 million$86.60 millionViewN/AView Earnings Details
11/5/2014Q3 2014$0.16($0.02)$71.00 million$62.47 millionViewN/AView Earnings Details
8/5/2014Q214$0.20$0.22$65.64 million$68.20 millionViewN/AView Earnings Details
5/6/2014Q114$0.23$0.16$62.19 million$51.00 millionViewN/AView Earnings Details
2/12/2014Q4$0.17$0.22ViewN/AView Earnings Details
11/6/2013Q313$0.11$0.13$62.10 million$53.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.12$50.00 million$59.30 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.10$0.23$53.70 million$59.40 millionViewN/AView Earnings Details
2/12/2013Q4 2012$0.09$0.17$56.49 million$59.10 millionViewN/AView Earnings Details
8/1/2012$0.02$0.01ViewN/AView Earnings Details
5/9/2012$0.05$0.02ViewN/AView Earnings Details
2/7/2012($0.12)($0.19)ViewN/AView Earnings Details
11/8/2011($0.05)($0.19)ViewN/AView Earnings Details
8/8/2011($0.03)($0.02)ViewN/AView Earnings Details
5/4/2011($0.14)($0.02)ViewN/AView Earnings Details
2/7/2011($0.15)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Albany Molecular Research (NASDAQ:AMRI)
2017 EPS Consensus Estimate: $1.02
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.11$0.11$0.11
Q2 20172$0.23$0.28$0.26
Q3 20172$0.15$0.19$0.17
Q4 20172$0.42$0.54$0.48
Q1 20181$0.22$0.22$0.22
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Albany Molecular Research (NASDAQ:AMRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Albany Molecular Research (NASDAQ AMRI)

Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 72.10%
Insider Trades by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Insider Trades by Quarter for Albany Molecular Research (NASDAQ AMRI)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016Anthony J MaddalunaDirectorBuy1,518$16.46$24,986.28View SEC Filing  
11/30/2016Steven R HagenSVPSell9,000$16.71$150,390.00View SEC Filing  
11/16/2016Lori M HendersonSVPSell6,000$17.00$102,000.00View SEC Filing  
11/10/2016Steven R HagenSVPSell785$16.79$13,180.15View SEC Filing  
8/9/2016Steven R HagenSVPSell1,401$15.29$21,421.29View SEC Filing  
5/31/2016Kevin OconnorDirectorSell5,000$14.41$72,050.00View SEC Filing  
5/16/2016William S MarthCEOBuy12,500$12.86$160,750.00View SEC Filing  
5/13/2016George SvokosCOOBuy12,500$12.82$160,250.00View SEC Filing  
5/13/2016Steven R HagenSVPSell2,361$12.77$30,149.97View SEC Filing  
11/9/2015Ambra Constance M DMajor ShareholderSell50,000$19.60$980,000.00View SEC Filing  
8/17/2015Steven R HagenSVPSell1,000$20.45$20,450.00View SEC Filing  
6/10/2015Ambra Constance M DMajor ShareholderSell20,000$19.77$395,400.00View SEC Filing  
6/8/2015Steven R HagenSVPSell5,000$19.99$99,950.00View SEC Filing  
6/4/2015William S MarthCEOBuy10,000$19.98$199,800.00View SEC Filing  
6/1/2015Stuart M CableMajor ShareholderSell30,000$19.69$590,700.00View SEC Filing  
5/11/2015Ambra Constance M DMajor ShareholderSell20,000$19.11$382,200.00View SEC Filing  
5/8/2015Steven R HagenSVPSell14,500$19.27$279,415.00View SEC Filing  
4/10/2015Ambra Constance M DMajor ShareholderSell20,000$18.50$370,000.00View SEC Filing  
3/17/2015Steven R HagenSVPSell3,500$18.53$64,855.00View SEC Filing  
3/12/2015Kevin OconnorDirectorSell5,000$18.22$91,100.00View SEC Filing  
3/10/2015Ambra Thomas E Phd DDirectorSell20,000$17.65$353,000.00View SEC Filing  
3/10/2015George SvokosInsiderBuy10,000$17.72$177,200.00View SEC Filing  
3/5/2015William S MarthCEOBuy20,000$17.70$354,000.00View SEC Filing  
3/2/2015Stuart M CableMajor ShareholderSell30,000$16.39$491,700.00View SEC Filing  
2/10/2015Ambra Thomas E Phd DDirectorSell20,000$16.91$338,200.00View SEC Filing  
2/2/2015Stuart M CableMajor ShareholderSell30,000$16.32$489,600.00View SEC Filing  
1/12/2015Ambra Thomas E Phd DDirectorSell20,000$16.45$329,000.00View SEC Filing  
1/7/2015Stuart M CableMajor ShareholderSell7,694$16.00$123,104.00View SEC Filing  
1/5/2015Stuart M CableMajor ShareholderSell22,306$16.21$361,580.26View SEC Filing  
12/10/2014Ambra Constance M DMajor ShareholderSell20,000$16.24$324,800.00View SEC Filing  
12/5/2014Stuart M CableMajor ShareholderSell13,307$16.00$212,912.00View SEC Filing  
12/4/2014Stuart M CableMajor ShareholderSell16,693$16.00$267,088.00View SEC Filing  
11/10/2014William S MarthCEOBuy30,000$17.01$510,300.00View SEC Filing  
10/10/2014Ambra Constance M DMajor ShareholderSell20,000$21.62$432,400.00View SEC Filing  
10/1/2014Lori M HendersonSVPSell1,000$21.48$21,480.00View SEC Filing  
10/1/2014Stuart M CableMajor ShareholderSell30,000$21.61$648,300.00View SEC Filing  
9/10/2014Ambra Constance M DMajor ShareholderSell20,000$20.12$402,400.00View SEC Filing  
9/2/2014Lori M HendersonSVPSell2,500$19.56$48,900.00View SEC Filing  
8/28/2014Steven R HagenSVPSell1,250$19.74$24,675.00View SEC Filing  
8/14/2014Michael M NolanCFOSell10,000$19.76$197,600.00View SEC Filing  
8/12/2014Lori M HendersonSVPSell30,000$19.05$571,500.00View SEC Filing  
8/11/2014Ambra Thomas E Phd DDirectorSell20,000$18.99$379,800.00View SEC Filing  
8/8/2014Steven R HagenSVPSell10,797$18.99$205,035.03View SEC Filing  
8/1/2014Lori M HendersonSVPSell2,500$18.56$46,400.00View SEC Filing  
8/1/2014Stuart M CableMajor ShareholderSell30,000$18.69$560,700.00View SEC Filing  
7/10/2014Ambra Thomas E Phd DDirectorSell20,000$20.94$418,800.00View SEC Filing  
7/1/2014Lori M HendersonSVPSell2,500$20.62$51,550.00View SEC Filing  
7/1/2014Stuart M CableMajor ShareholderSell30,000$21.00$630,000.00View SEC Filing  
6/3/2014Steven R HagenSVPSell2,500$16.93$42,325.00View SEC Filing  
5/16/2014Steven HagenSVPSell1,250$15.45$19,312.50View SEC Filing  
5/15/2014George SvokosSVPBuy10,000$15.60$156,000.00View SEC Filing  
5/12/2014Steven HagenSVPSell5,897$15.00$88,455.00View SEC Filing  
5/12/2014William MarthCEOBuy30,000$15.40$462,000.00View SEC Filing  
5/1/2014Lori HendersonVPSell2,500$15.73$39,325.00View SEC Filing  
5/1/2014Stuart Cablemajor shareholderSell30,000$15.98$479,400.00View SEC Filing  
4/1/2014Lori HendersonVPSell2,500$18.74$46,850.00View SEC Filing  
4/1/2014Stuart Cablemajor shareholderSell30,000$18.52$555,600.00View SEC Filing  
2/27/2014Arthur RothDirectorSell5,000$15.95$79,750.00View SEC Filing  
2/27/2014Steven HagenSVPSell3,000$15.73$47,190.00View SEC Filing  
2/25/2014Steven HagenSVPSell2,500$15.19$37,975.00View SEC Filing  
2/24/2014Michael NolanCFOSell15,000$15.00$225,000.00View SEC Filing  
2/21/2014Steven HagenSVPSell1,500$14.87$22,305.00View SEC Filing  
2/19/2014Steven HagenSVPSell1,500$13.37$20,055.00View SEC Filing  
2/13/2014Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
12/4/2013Steven HagenSVPSell2,500$10.93$27,325.00View SEC Filing  
12/3/2013William MarthDirectorBuy30,000$10.75$322,500.00View SEC Filing  
11/22/2013Steven HagenSVPSell2,300$11.55$26,565.00View SEC Filing  
11/22/2013William MarthDirectorBuy20,000$11.57$231,400.00View SEC Filing  
9/13/2013Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
8/1/2013Stuart M CableMajor ShareholderSell30,000$12.53$375,900.00View SEC Filing  
7/1/2013Stuart M CableMajor ShareholderSell30,000$12.47$374,100.00View SEC Filing  
6/12/2013Stuart M CableMajor ShareholderSell30,000$12.00$360,000.00View SEC Filing  
5/22/2013Bruce J SargentSVPSell7,500$10.97$82,275.00View SEC Filing  
5/10/2013Steven R HagenSVPSell1,200$10.40$12,480.00View SEC Filing  
12/3/2012William S MarthDirectorBuy10,000$5.00$50,000.00View SEC Filing  
11/15/2012Ambra Thomas E Phd DCEOBuy10,000$3.80$38,000.00View SEC Filing  
8/9/2012Steven R HagenVPSell3,000$3.00$9,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Albany Molecular Research (NASDAQ AMRI)

Source:
DateHeadline
The drug discovery services market was valued at USD 8.32 billion in 2017 and expected to grow at a CAGR of 11.6% to reach USD 14.40 billion in 2022The drug discovery services market was valued at USD 8.32 billion in 2017 and expected to grow at a CAGR of 11.6% to reach USD 14.40 billion in 2022
www.bizjournals.com - November 7 at 5:36 PM
The drug discovery services market was valued at USD 8.32 billion in 2017 and expected to grow at a CAGR of 11.6% to reach USD 14.40 billion in 2022The drug discovery services market was valued at USD 8.32 billion in 2017 and expected to grow at a CAGR of 11.6% to reach USD 14.40 billion in 2022
www.bizjournals.com - November 7 at 5:36 PM
Cohen Lawrence B Buys TJX Inc, United Technologies Corp, US Bancorp, Sells Ford Motor Co, ...Cohen Lawrence B Buys TJX Inc, United Technologies Corp, US Bancorp, Sells Ford Motor Co, ...
www.nasdaq.com - November 4 at 10:23 PM
Albany Molecular Research (AMRI) versus OncoMed Pharmaceuticals (OMED) Critical ReviewAlbany Molecular Research (AMRI) versus OncoMed Pharmaceuticals (OMED) Critical Review
www.americanbankingnews.com - November 1 at 11:12 PM
Drug Discovery Services Market Worth 14.40 Billion USD by 2022Drug Discovery Services Market Worth 14.40 Billion USD by 2022
www.marketwatch.com - October 27 at 11:02 PM
Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Albany Molecular Research, Inc.Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Albany Molecular Research, Inc.
finance.yahoo.com - October 25 at 4:55 PM
Albany Molecular Research (AMRI) & Its Competitors Financial ReviewAlbany Molecular Research (AMRI) & Its Competitors Financial Review
www.americanbankingnews.com - October 23 at 6:28 PM
AMRI says its still committed to Buffalo project after private equity takeoverAMRI says it's still committed to Buffalo project after private equity takeover
www.bizjournals.com - October 21 at 3:39 PM
Albany Molecular Research (AMRI) & Its Competitors Head-To-Head ComparisonAlbany Molecular Research (AMRI) & Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - October 17 at 8:26 AM
Brown Trout Management, LLC Buys IXYS Corp, First South Bancorp, Paragon Commercial Corp, Sells ...Brown Trout Management, LLC Buys IXYS Corp, First South Bancorp, Paragon Commercial Corp, Sells ...
www.nasdaq.com - October 12 at 4:38 PM
Head to Head Review: Albany Molecular Research (AMRI) versus Its RivalsHead to Head Review: Albany Molecular Research (AMRI) versus Its Rivals
www.americanbankingnews.com - October 1 at 12:18 PM
Albany Molecular Research (AMRI) vs. Corvus Pharmaceuticals (CRVS) Head to Head AnalysisAlbany Molecular Research (AMRI) vs. Corvus Pharmaceuticals (CRVS) Head to Head Analysis
www.americanbankingnews.com - September 20 at 4:28 AM
Albany Business Review announces 2017 AchieversAlbany Business Review announces 2017 Achievers
www.bizjournals.com - September 14 at 3:05 AM
3ST Research Files Litigation Alleging Fraud and Conversion of Inventors Intellectual Property Rights by Albany Molecular Research Inc. (AMRI)3ST Research Files Litigation Alleging Fraud and Conversion of Inventor's Intellectual Property Rights by Albany Molecular Research Inc. (AMRI)
finance.yahoo.com - September 12 at 4:05 PM
Albany Molecular Research, Inc. (AMRI) Expected to Post Quarterly Sales of $171.94 MillionAlbany Molecular Research, Inc. (AMRI) Expected to Post Quarterly Sales of $171.94 Million
www.americanbankingnews.com - September 1 at 3:06 AM
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCRAMRI Announces Completion of Acquisition by The Carlyle Group and GTCR
finance.yahoo.com - August 31 at 3:40 PM
AMRI shareholders approve sale of companyAMRI shareholders approve sale of company
finance.yahoo.com - August 18 at 4:01 PM
Albany Molecular Research, Inc. (NASDAQ:AMRI) Expected to Announce Earnings of $0.23 Per ShareAlbany Molecular Research, Inc. (NASDAQ:AMRI) Expected to Announce Earnings of $0.23 Per Share
www.americanbankingnews.com - August 12 at 2:26 PM
Albany Molecular Research, Inc. (AMRI) Expected to Announce Quarterly Sales of $171.94 MillionAlbany Molecular Research, Inc. (AMRI) Expected to Announce Quarterly Sales of $171.94 Million
www.americanbankingnews.com - July 27 at 3:05 PM
Albany Molecular Research, Inc. (NASDAQ:AMRI) to Release Quarterly Earnings on WednesdayAlbany Molecular Research, Inc. (NASDAQ:AMRI) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:12 AM
Albany Molecular Research, Inc. (AMRI) Expected to Announce Earnings of $0.23 Per ShareAlbany Molecular Research, Inc. (AMRI) Expected to Announce Earnings of $0.23 Per Share
www.americanbankingnews.com - July 25 at 9:20 AM
Albany Molecular Research, Inc. -- Moodys assigns B3 CFR to UIC Merger Sub, Inc. (dba Albany Molecular Research, Inc.)Albany Molecular Research, Inc. -- Moody's assigns B3 CFR to UIC Merger Sub, Inc. (dba Albany Molecular Research, Inc.)
finance.yahoo.com - July 19 at 5:02 PM
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Albany Molecular Research, Inc. – AMRIThe Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Albany Molecular Research, Inc. – AMRI
finance.yahoo.com - July 17 at 4:10 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI)
finance.yahoo.com - July 13 at 4:35 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Albany Molecular Research, Inc. - AMRISHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Albany Molecular Research, Inc. - AMRI
finance.yahoo.com - July 5 at 9:00 PM
 Analysts Anticipate Albany Molecular Research, Inc. (AMRI) Will Post Quarterly Sales of $171.94 Million Analysts Anticipate Albany Molecular Research, Inc. (AMRI) Will Post Quarterly Sales of $171.94 Million
www.americanbankingnews.com - July 1 at 10:04 AM
AMRI chief gives a billion reasons why the company is about to be soldAMRI chief gives a billion reasons why the company is about to be sold
www.bizjournals.com - July 1 at 1:56 AM
Carlyle Group takes out Albany Molecular Research for $21.75/share; +9% premarketCarlyle Group takes out Albany Molecular Research for $21.75/share; +9% premarket
seekingalpha.com - June 6 at 8:34 PM
GTCR and Carlyle Group are buying Albany Molecular Research for $922 millionGTCR and Carlyle Group are buying Albany Molecular Research for $922 million
www.businessinsider.com - June 6 at 8:34 PM
Albany Molecular Research (AMRI) Agrees to Be Acquired by The Carlyle Group and GTCR for $21.75/ShareAlbany Molecular Research (AMRI) Agrees to Be Acquired by The Carlyle Group and GTCR for $21.75/Share
www.streetinsider.com - June 6 at 8:34 PM
Exclusive: GTCR, Carlyle in talks to acquire Albany Molecular Research - sourcesExclusive: GTCR, Carlyle in talks to acquire Albany Molecular Research - sources
www.reuters.com - June 5 at 6:25 PM
Global Contract Research Outsourcing - ServicesGlobal Contract Research Outsourcing - Services
www.bizjournals.com - May 29 at 3:55 PM
Morgan Stanley Downgrades Albany Molecular Research Inc. (AMRI) to EqualweightMorgan Stanley Downgrades Albany Molecular Research Inc. (AMRI) to Equalweight
www.streetinsider.com - May 11 at 3:53 PM
Morgan Stanley Downgrades Albany Molecular Research Inc. (AMRI) to EqualweightMorgan Stanley Downgrades Albany Molecular Research Inc. (AMRI) to Equalweight
www.streetinsider.com - May 11 at 3:53 PM
Albany Molecular Research, Inc. 2017 Q1 - Results - Earnings Call SlidesAlbany Molecular Research, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 10 at 3:43 PM
Albany Molecular Research posts 1Q lossAlbany Molecular Research posts 1Q loss
marketbeat.com - May 9 at 8:43 AM
AMRI will bring work from newly awarded federal grant to Buffalo, where it will soon have 40 employeesAMRI will bring work from newly awarded federal grant to Buffalo, where it will soon have 40 employees
www.bizjournals.com - May 2 at 3:36 PM
BRIEF-Albany Molecular Research says AMRI receives NIH contract awardBRIEF-Albany Molecular Research says AMRI receives NIH contract award
www.reuters.com - May 2 at 3:36 PM
Denovo Biopharma Obtains Exclusive License to Liafensine from Albany Molecular Research (AMRI)Denovo Biopharma Obtains Exclusive License to Liafensine from Albany Molecular Research (AMRI)
www.streetinsider.com - April 24 at 10:42 AM
BRIEF-Albany Molecular Research files for secondary offering of 2.2 mln sharesBRIEF-Albany Molecular Research files for secondary offering of 2.2 mln shares
www.reuters.com - March 17 at 4:13 PM
ALBANY MOLECULAR RESEARCH INC Files SEC form 10-K, Annual ReportALBANY MOLECULAR RESEARCH INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 5:01 PM
AMRI boosts revenue by 42 percentAMRI boosts revenue by 42 percent
www.bizjournals.com - February 23 at 8:34 PM
Albany Molecular Research, Inc. 2016 Q4 - Results - Earnings Call SlidesAlbany Molecular Research, Inc. 2016 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 22 at 8:32 PM
BRIEF-Albany Molecular Research enters into agreement with pharmaceutical group Ferrer, Accord HealthcareBRIEF-Albany Molecular Research enters into agreement with pharmaceutical group Ferrer, Accord Healthcare
www.reuters.com - February 22 at 8:32 PM
Albany Molecular Research 4Q Misses Street (AMRI)Albany Molecular Research 4Q Misses Street (AMRI)
www.investopedia.com - February 22 at 8:32 PM
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in DirectorsALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors
biz.yahoo.com - February 22 at 11:32 AM
Albany Molecular Research 4Q Net Misses StreetAlbany Molecular Research 4Q Net Misses Street
www.investopedia.com - February 22 at 11:32 AM
AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 OutlookAMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook
us.rd.yahoo.com - February 21 at 3:47 PM
AMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize Parenteral Drug ProductsAMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products
us.rd.yahoo.com - February 21 at 3:47 PM
Q4 2016 Albany Molecular Research Inc Earnings Release - Before Market OpenQ4 2016 Albany Molecular Research Inc Earnings Release - Before Market Open
biz.yahoo.com - February 21 at 7:27 AM

Social Media

Financials

Chart

Albany Molecular Research (NASDAQ AMRI) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.